• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

    3/17/23 8:15:00 AM ET
    $APM
    $ASPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials
    Get the next $APM alert in real time by email

    ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_access

    ASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_access

    About The RedChip Money Report®

    The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

    About Aptorum Group Limited

    Aptorum Group Limited (NASDAQ:APM, PARIS:APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases. Aptorum has completed two phase I clinical trials for its ALS-4 (MRSA) and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell® nutraceutical (menopause). The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore's Agency for Science, Technology and Research.

    For more information about the Company, please visit www.aptorumgroup.com.

    About ASP Isotopes Inc.

    ASPI is an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries. We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process ("ASP technology") for the production, distribution, marketing and sale of all isotopes.

    Our initial focus is on the production and commercialization of enriched Carbon-14, Silicon-28 and Molybdenum-100 ("Mo-100"), and we are constructing two commercial scale isotope enrichment plants in Pretoria, South Africa. We believe Silicon-28 has the potential use in advanced semiconductors and the quantum computing end markets, and Carbon-14, which has potential application in the pharma/agrochemical target end market. We believe that the Mo-100 we plan to develop using our technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.

    In addition, we are considering future development of its facilities for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Uranium-235, Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market.

    We are incorporated in Delaware in September 2021. Our principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, and our telephone number is (561) 709-3034. Our website address is www.aspisotopes.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/744354/Aptorum-Group-Limited-and-ASP-Isotopes-Inc-Interviews-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR

    Get the next $APM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $APM
    $ASPI
    SEC Filings

    View All

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    11/21/25 8:23:55 AM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by ASP Isotopes Inc.

    10-Q - ASP Isotopes Inc. (0001921865) (Filer)

    11/19/25 4:31:06 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form DEL AM filed by Aptorum Group Limited

    DEL AM - Aptorum Group Ltd (0001734005) (Filer)

    11/18/25 4:30:13 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

    NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. Details

    11/19/25 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASP Isotopes to Provide Quarterly Business Update Call on November 21, 2025 at 8:30am EST

    WASHINGTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced it will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. (Eastern Time). Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Webcast Link https://events.q4inc.com/attendee/428149635 Participant Dial-In Details Date: November 21, 2025Time: 8:30 a.m. ESTDial in: USA / International Tol

    11/17/25 4:31:40 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Announces Quantum Leap Energy's Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

    WASHINGTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) today announced that its wholly-owned subsidiary, Quantum Leap Energy LLC ("QLE"), has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of QLE's Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed initial public offering remains subject to the completion of the SEC review process as well as market and other conditions. This press release is being issued pursuant to, and in accordance with, Rule 135 p

    11/12/25 5:17:56 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $APM
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim CEO and COO Ainscow Robert sold $506,722 worth of shares (67,500 units at $7.51), decreasing direct ownership by 4% to 1,579,693 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    11/19/25 9:03:39 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Director Wider Todd was granted 25,469 shares, increasing direct ownership by 4% to 735,699 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    11/14/25 9:34:57 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Interim CEO and COO Ainscow Robert sold $305,978 worth of shares (22,500 units at $13.60), decreasing direct ownership by 1% to 1,647,193 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    10/16/25 9:16:59 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $APM
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

    Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

    10/4/24 7:13:36 AM ET
    $ASPI
    Major Chemicals
    Industrials

    H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

    H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

    12/5/23 7:36:42 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $APM
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/10/24 5:59:47 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $APM
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

    Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) --  -Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company  -Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited (NASDAQ:SKBL), a Cayman Islands exempted company (the "Company"), today announced a number of strategic changes to the Company's leadership, strategy and corporate headquarters. Appointment of Paul Mann as Executive Chairman Effective January 1, 2026, Paul E. Mann will become Executive Chairman of the Company. Mr. Mann has a 25-year career as an investor and entrepreneur. He is currently the Founder and Executiv

    11/6/25 8:15:00 AM ET
    $ASPI
    $SKBL
    Major Chemicals
    Industrials
    Engineering & Construction
    Consumer Discretionary

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $APM
    $ASPI
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes to Provide Quarterly Business Update Call on November 21, 2025 at 8:30am EST

    WASHINGTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced it will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. (Eastern Time). Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Webcast Link https://events.q4inc.com/attendee/428149635 Participant Dial-In Details Date: November 21, 2025Time: 8:30 a.m. ESTDial in: USA / International Tol

    11/17/25 4:31:40 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/14/24 3:01:19 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

    SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

    11/7/24 4:15:14 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

    SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

    4/16/24 4:32:40 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care